Oncorus to Present Initial Data from its Ongoing Phase 1 Clinical Trial of ONCR-177 at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
October 01, 2021 08:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights
August 04, 2021 07:00 ET
|
Oncorus, Inc.
Continues to progress Phase 1 clinical trial of ONCR-177, company’s lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate; on track to report initial interim data in 4Q’21Nominated...
Oncorus Expands its Board with Appointment of Barbara Yanni
July 29, 2021 07:00 ET
|
Oncorus, Inc.
-- Former Merck executive brings extensive experience in corporate development, licensing and financial evaluation, and expertise advising clinical stage public biopharmaceutical companies -- ...
Oncorus Appoints Eric Rubin, M.D. to its Board of Directors
June 17, 2021 07:00 ET
|
Oncorus, Inc.
-- Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA® (pembrolizumab) -- CAMBRIDGE,...
Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates
June 15, 2021 07:57 ET
|
Oncorus, Inc.
Virtual event will take place on June 21, 2021 from 1:00 – 2:30 p.m. ETOncorus’ novel approach leverages selectively self-amplifying vRNA encoding for oncolytic viruses encapsulated within lipid...
Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788
May 27, 2021 07:05 ET
|
Oncorus, Inc.
Pioneering Synthetic vRNA immunotherapies that are composed of self-amplifying vRNA encoding for oncolytic viruses encapsulated within lipid nanoparticles (LNPs)Novel approach engineered to produce a...
Oncorus to Present at Upcoming Jefferies Virtual Healthcare Conference
May 26, 2021 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights
May 04, 2021 07:00 ET
|
Oncorus, Inc.
-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H’21 -- ...
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
March 10, 2021 07:00 ET
|
Oncorus, Inc.
2020 marked year of notable progress for Oncorus. Key highlights included: Transitioned to clinical-stage company with initiation of Phase 1 clinical trial of lead viral immunotherapy candidate,...
Oncorus Announces Pricing of Public Offering of Common Stock
February 11, 2021 22:15 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to...